Cancer News

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes (02/03/2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were published in The Lancet Oncology, and presented at the 2016 annual meeting of the American Society of Hematology (ASH). Smoldering myeloma is considered to be a pre-cancerous condition, in which …

Continue reading "Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes"